Text Size:AAA

マウス CD80/B7-1  タンパク質

All CD80 Reagents

製品の説明: Active  
発現宿主: Human Cells  
200 µg 
100 µg 
Add to Cart
  • Slide 1
製品の説明: Active  
発現宿主: Human Cells  
200 µg 
100 µg 
Add to Cart
  • Slide 1

Browse CD80/B7-1 Products by

CD80/B7-1 Related Area

CD80/B7-1 関連経路

    CD80/B7-1 関連製品

    CD80/B7-1 関連製品

    Featured Reagent Products

    CD80/B7-1 サマリー & タンパク質情報

    CD80/B7-1 背景

    遺伝子の概要: The protein encoded by this CD80 gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. CD80 can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy. [provided by RefSeq, Aug 2011]
    General information above from NCBI
    サブユニット構造: Homodimer; CD80 dimers on the antigen presenting cells (APCs) bridge CTLA4/CD152 dimers on T-cells in a periodic zipper-like arrangement. Interacts with adenovirus subgroup B fiber proteins and acts as a receptor for these viruses. {ECO:0000269|PubMed:10583602, ECO:0000269|PubMed:11279502, ECO:0000269|PubMed:16920215}.
    細胞内位置: Membrane; Single-pass type I membrane protein.
    組織特異性: Expressed on activated B-cells, macrophages and dendritic cells.
    シーケンスの類似性: Contains 1 Ig-like C2-type (immunoglobulin-like) domain. {ECO:0000305}.; Contains 1 Ig-like V-type (immunoglobulin-like) domain. {ECO:0000305}.
    General information above from UniProt

    The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

    Immune Checkpoint
    Immune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies   Immune Checkpoint Detection: IHC Antibodies   Immune Checkpoint Detection: FCM Antibodies   Immune Checkpoint Detection: WB Antibodies
    Immune Checkpoint Proteins
    Immune Checkpoint Targets   Co-inhibitory Immune Checkpoint Targets

    Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    CD80/B7-1 代替名

    CD80/B7-1 関連研究

  • Greenfield EA, et al. (1998) CD28/B7 costimulation: a review. Crit Rev Immunol. 18(5): 389-418.
  • Zang X, et al. (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 13(18 Pt 1): 5271-9.
  • Mir MA, et al. (2008) Signaling through CD80: an approach for treating lymphomas. Expert Opin Ther Targets. 12(8): 969-79.
  • 注意:すべての製品は、"研究目的のみに使用するものであり、診断または治療目的に使用するものではありません"